Medical Doctor Program year 2023 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Joseph Camps

Urology Tallahassee, FL Medical Doctor

NPI 1083678254 CMS profile 94562

2000 Centre Pointe Blvd, Tallahassee, FL 32308

Open in the dashboard

General payments

$6,565

340 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$66,547

7 holdings reported · through program year 2023

Through program year 2023, Joseph Camps of Tallahassee, FL is reported in the CMS Open Payments database as having received $6,565 across 340 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $66,547 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $937 44
2022 General $1,089 55
2021 General $1,730 86
2020 General $1,275 66
2019 General $1,534 89
2024 Ownership $14,921 2
2023 Ownership $14,628 1
2022 Ownership $6,931 1
2021 Ownership $6,436 1
2020 Ownership $16,503 1
2019 Ownership $7,127 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Camps
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Joseph Camps were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Joseph Camps Urology median Middle half National median
2019 $1,534 $480 $147–$1,201 $163
2020 $1,275 $246 $87–$645 $114
2021 $1,730 $358 $111–$1,000 $132
2022 $1,089 $476 $143–$1,263 $149
2023 $937 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Pfizer Inc. $682 38 payments
  2. KARL STORZ Endoscopy-America $592 10 payments
  3. Astellas Pharma US Inc $571 39 payments
  4. Janssen Biotech, Inc. $530 31 payments
  5. Allergan Inc. $465 26 payments
  6. Amgen Inc. $375 20 payments
  7. Myriad Genetic Laboratories, Inc. $322 18 payments
  8. Endo Pharmaceuticals Inc. $317 15 payments
  9. AbbVie, Inc. $310 16 payments
  10. Coloplast Corp $306 16 payments
  11. Other $2,096 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,551 339 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2023
  1. XTANDI $725 42 payments
  2. BOTOX $566 31 payments
  3. ERLEADA $530 31 payments
  4. MYRBETRIQ $511 34 payments
  5. XIAFLEX $317 15 payments
  6. AVEED $296 14 payments
  7. XGEVA $296 15 payments
  8. ORGOVYX $284 14 payments
  9. Prolia $273 15 payments
  10. EDEX $256 12 payments
  11. Other $4,146 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

197

Median for Urology: 1,053

Drug cost

$14,726

Median for Urology: $101,464

Branded share of claims

8.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 17 $10,675
Tamsulosin Hcl Generic 113 $1,639
Silodosin Generic 17 $1,178
Solifenacin Succinate Generic 18 $620
Finasteride Generic 17 $350
Trimethoprim Generic 15 $265

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record